ADAMA, a leading global crop protection company, and ALRISE Biosystems, a drug-delivery company focused on advanced microencapsulation of active ingredients, recently announced the signature of an R&D agreement to develop new innovative and sustainable crop protection products with ALRISE’s proprietary ImSus encapsulation technology.
Through this partnership, ADAMA and ALRISE aim to deliver new, highly effective crop protection products to farmers with a lower dose of active ingredients.
“ALRISE has been active in the field of pharmaceuticals for more than 16 years. The collaboration with ADAMA opens a whole new range of applications”, stated Dr. VolkerRindler, ALRISE’s Managing Director. “We are pleased to offer our technology to a world leader in the agrochemical field and to contribute to developing innovative and sustainable crop protection products to meet the demand for more environmentally friendly solutions”, Dr. Heiko Seemann, ALRISE’s Managing Director, added.
Dr. Elad Shabtai, VP Innovation, Development and Research, and Regulatory Affairs, at ADAMA said that “the microencapsulation technology can bring significant benefits to the agrochemical sector, as it allows an increase of water solubility and bioavailability as well as a reduction of dosing frequency. The partnership with ALRISE taps into ADAMA’s promise to deliver highly effective and sustainable solutions to farmers.”
Adama Agricultural Solutions Ltd., together with Hubei Sanonda Ltd, to be known as ADAMA, is one of the world's leading crop protection companies. We strive to Create Simplicity in Agriculture – offering farmers effective products and services that simplify their lives and help them grow. With one of the most comprehensive and diversified portfolios of differentiated, quality products, our 6,600-strong team reaches farmers in over 100 countries, providing them with solutions to control weeds, insects and disease, and improve their yields. For more information, visit us at www.adama.com and follow us on Twitter® at @AdamaAgri.
About ALRISE Biosystems:
Alrise was founded in 2004 by Dr. Celal Albayrak, Dr. Volker Rindler and Dr. Heiko Seemann. In collaboration with pharmaceutical companies Alrise develops injectable as well as oral formulations based on polymeric nano- and microparticles for various substance classes. Major shareholders in the Berlin-based company are the VC companies Creathor Venture and IBB Beteiligungsgesellschaft mbH as well as Dr. Giuseppe Vita, the former CEO of Schering AG. For more information, visit www.alrise.de